AMRIX (cyclobenzaprine hydrochloride) by Teva is function. First approved in 2007.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AMRIX is an extended-release oral capsule formulation of cyclobenzaprine hydrochloride, a centrally acting skeletal muscle relaxant approved in 2007. It reduces muscle spasm by decreasing tonic somatic motor activity at the brainstem level, with effects on both gamma and alpha motor systems. AMRIX is used for acute muscle spasm relief and is structurally related to tricyclic antidepressants, producing sedation and anticholinergic effects.
Product approaching loss of exclusivity with minimal Medicare Part D activity (202 claims in 2023), suggesting a mature, niche product with limited team expansion opportunities.
function. Cyclobenzaprine has not been shown to be effective in muscle spasm due to central nervous system disease. In animal models, cyclobenzaprine reduced or abolished skeletal muscle hyperactivity. Animal studies indicate that cyclobenzaprine does not act at the neuromuscular junction or…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules
Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine
Worked on AMRIX at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moAMRIX presents limited career growth opportunities as a mature, LOE-approaching product with minimal linked job postings and declining commercial relevance. Professionals joining this team should expect stability in existing roles rather than advancement or expansion, making it suitable for those seeking a stable position in a niche therapeutic area rather than high-growth career trajectory.